Table 1.
Patient characteristics.
| Cohort AHealthy persons(n=15) | Cohort BCancer patients IMT treatment (n=14) | Cohort CCancer patients no-IMT treatment (n=6) | |
|---|---|---|---|
| Characteristics | |||
| Age – y, Median (range) | 53 (26-72) | 67 (38-84) | 59 (47-61) |
| Sex – n (%) | |||
| Female | 8 (53) | 7 (50) | 4 (67) |
| ECOG PS – n (%) | |||
| 0 | 15 (100) | 7 (50) | 4 (67) |
| 1 | 0 | 7 (50) | 2 (33) |
| Cancer type– n (%) | |||
| Non-squamous NSCLC | NA | 7 (50) | 2 (33) |
| Squamous NSCLC | NA | 3 (21) | 0 |
| Melanoma | NA | 3 (21) | 2 (33) |
| Colon cancer | NA | 1 (6) | 0 |
| Breast cancer | NA | 2 (33) | |
| Tumor stage – n (%) | |||
| II | NA | 1 (7) | 1 (17) |
| III | NA | 3 (21) | 0 |
| IV | NA | 10 (71) | 5 (83) |
| Cancer control – n (%) | |||
| No active disease | NA | 3 (21) | 1 (17) |
| Complete response | NA | 6 (43) | 2 (33) |
| Partial response | NA | 5 (36) | 2 (33) |
| Progression disease | NA | 0 | 1 (17) |
| Anticancer drug– n (%) | |||
| Nivolumab | 0 | 2 (14) | 0 |
| Pembrolizumab | 0 | 6 (43) | 0 |
| Durvalumab | 0 | 1 (7) | 0 |
| Atezolizumab | 0 | 3 (21) | 0 |
| Pembrolizumab-ChT | 0 | 1 (7) | 0 |
| Nivolumab-bempegaldesleukin | 0 | 1 (7) | 0 |
| Cht | 0 | 0 | 2 (33) |
| BRAFi-MEKi | 0 | 0 | 1 (17) |
| Hormonotherapy | 0 | 0 | 2 (33) |
| No anticancer treatment | 0 | 0 | 1 (17) |
NA, Not applicable.